TGF-β (Transforming Growth Factor-beta) Modulation Therapy represents a sophisticated approach to treating neurodegenerative diseases by targeting the dysregulated TGF-β signaling pathway. This pathway plays a dual role in neurodegeneration—promoting neuronal survival under physiological conditions while contributing to disease progression when chronically dysregulated. Therapeutic modulation aims to restore the delicate balance of TGF-β signaling to achieve neuroprotection without exacerbating neuroinflammation. [@krieglstein1995]
The TGF-β superfamily comprises multiple ligands that signal through serine/threonine kinase receptors: [@chao2009]
- TGF-β1: Primarily involved in immune modulation and neuroinflammation
- TGF-β2: Critical for oligodendrocyte differentiation and myelination
- TGF-β3: Promotes neuronal survival and synaptic plasticity
- Ligand Binding: TGF-β ligands bind to constitutively active TβRII (TGF-β Receptor II)
- Receptor Complex Formation: TβRII recruits and phosphorylates TβRI (ALK5/TGF-β Receptor I)
- SMAD Activation: Activated TβRI phosphorylates receptor-regulated SMADs (R-SMADs)
- Nuclear Translocation: SMAD2/3 complexes with SMAD4 and translocates to the nucleus
- Transcriptional Regulation: The complex regulates target genes involved in:
- Neuroinflammation (cytokine production, microglial activation)
- Neurogenesis (neuronal differentiation, survival)
- Synaptic plasticity (receptor trafficking, dendritic morphology)
- Extracellular matrix remodeling (astrocyte reactivity, fibrosis)
TGF-β also activates alternative signaling cascades: [@endo2015]
- MAPK/ERK Pathway: Regulates neuronal differentiation and survival
- PI3K/Akt Pathway: Promotes neuronal survival, counteracts apoptosis
- p38/JNK Pathway: Pro-inflammatory signaling, stress-activated
TGF-β modulates neuroinflammation through multiple mechanisms: [@phatnani2013]
- Microglial Phenotype Regulation: TGF-β shifts microglia from pro-inflammatory (M1) to anti-inflammatory (M2) phenotype
- Cytokine Production: Inhibits production of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α)
- NF-κB Cross-talk: TGF-β signaling intersects with NF-κB pathway at multiple levels
Astrocytes are critical targets for TGF-β modulation: [@blurtonjones2009]
- Reactive Astrocytosis: Chronic TGF-β elevation promotes pro-inflammatory astrocyte phenotype
- Aβ Clearance: TGF-β modulates astrocytic phagocytosis of amyloid-beta
- Neuronal Support: TGF-β regulates astrocytic production of neurotrophic factors
| Study | Model | Intervention | Outcome | [@krieglstein2012]
|-------|-------|--------------|---------| [@ueberham2020]
| Wyss-Coray et al., 2000 | APP transgenic mice | TGF-β1 overexpression | Reduced Aβ plaques, improved cognition | [@wysscoray2001]
| Tesseur et al., 2006 | Neuronal TGF-β deficiency | TGF-β expression | Accelerated Aβ pathology | [@yousef2019]
| Blurton-Jones et al., 2009 | Neural stem cells | TGF-β secretion | Enhanced Aβ clearance | [@van2012]
Key Findings: [@galunisertib]
- TGF-β1 overexpression in astrocytes reduces amyloid plaque burden by 50-80%
- TGF-β deficiency in neurons accelerates Aβ pathology and cognitive decline
- TGF-β enhances microglial and astrocytic Aβ phagocytosis
| Study |
Model |
Intervention |
Outcome |
| Sortwell et al., 2000 |
6-OHDA rats |
TGF-β1 delivery |
Protected dopaminergic neurons |
| Krieglstein et al., 1995 |
MPTP mice |
TGF-β1 |
Prevented dopaminergic neuron loss |
| Tesseur et al., 2006 |
α-syn transgenic |
TGF-β modulation |
Modulated α-syn aggregation |
Key Findings:
- TGF-β1 and TGF-β3 promote dopaminergic neuron survival through PI3K/Akt signaling
- TGF-β modulates microglial activation and neuroinflammation in PD models
- TGF-β signaling intersects with LRRK2 pathways
| Study |
Model |
Intervention |
Outcome |
| Endo et al., 2015 |
SOD1 mice |
TGF-β blockade |
Delayed disease progression |
| Phatnani et al., 2013 |
ALS patient cells |
SMAD dysfunction |
Identified pathway impairment |
| Lookingland et al., 2024 |
ALS models |
Galunisertib |
Phase 2 trial ongoing |
Key Findings:
- Elevated TGF-β1 in ALS patient CSF and spinal cord tissue
- TDP-43 pathology sequesters SMAD proteins, impairing signaling
- TGF-βR1 inhibition (galunisertib) shows promise in preclinical models
¶ Active and Recent Trials
-
Galunisertib (LY2109761) in ALS
- Phase 2a trial (NCT05328847)
- TGF-βR1 (ALK5) inhibitor combined with PDE4 inhibitor (nerandomilast)
- Targets GREM2-positive ALS patients with heightened TGF-β/SMAD-driven signaling
- Status: NOT_YET_RECRUITING
- Outcome measures: GREM2 and TGF-β pathway marker levels
-
Fresolimumab (GC1008)
- Anti-TGF-β1 antibody
- Previously studied in oncology and idiopathic pulmonary fibrosis
- Potential for neuroinflammatory conditions
| Agent |
Mechanism |
Development Stage |
Indication |
| Recombinant TGF-β1 |
Direct ligand |
Preclinical |
PD, HD |
| BMP-7 (Osteogenic Protein-1) |
BMP pathway activation |
Phase II (withdrawn) |
PD |
| AAV-TGF-β1 |
Gene therapy |
Preclinical |
AD |
| Agent |
Mechanism |
Development Stage |
Indication |
| SB-431542 |
TβRI kinase inhibitor |
Preclinical |
ALS |
| SD-208 |
TβRI kinase inhibitor |
Preclinical |
ALS, PD |
| LY2109761 (Galunisertib) |
TβRI/II dual inhibitor |
Phase II |
ALS |
| Fresolimumab |
Anti-TGF-β1 antibody |
Phase I/II |
Oncology |
- SMAD7 gene therapy: Restore inhibitory SMAD7 signaling to normalize TGF-β pathway
- Antisense oligonucleotides: Target SMAD7 to enhance canonical TGF-β signaling
- BET inhibitors: Modulate SMAD-dependent transcription
¶ Risks and Concerns
TGF-β Agonists:
- Risk of excessive immunosuppression
- Potential for fibrotic complications
- Dose-dependent effects on multiple organ systems
TGF-β Antagonists:
- Risk of increased neuroinflammation
- Potential for enhanced protein aggregation
- Impact on neuronal survival mechanisms
- Serum TGF-β1 levels
- CSF biomarkers (p-SMAD2/3, SMAD7)
- Neuroimaging for fibrotic changes
- Immune function markers
The key challenge is achieving therapeutic benefit without disrupting the delicate balance of TGF-β signaling:
- Low/moderate TGF-β: Insufficient neuroprotection
- Excessive TGF-β: Neuroinflammation and fibrosis
- Optimal modulation: Pathway normalization rather than complete blockade
¶ Cross-Links and Related Pages
¶ Gene and Protein Pages
TGF-β Modulation Therapy represents a promising but nuanced approach to neurodegenerative disease treatment. The dual nature of TGF-β signaling—neuroprotective in some contexts and pathogenic in others—demands careful therapeutic targeting. Current strategies include:
- TGF-β agonists to enhance neurotrophic support and Aβ clearance
- TGF-β antagonists to reduce chronic neuroinflammation
- SMAD7 modulation to restore canonical signaling balance
- Combination approaches targeting multiple nodes of the pathway
The ongoing Phase 2 trial of galunisertib in ALS marks an important milestone in translating TGF-β research into clinical therapy. Success will depend on identifying the right patient subgroups and achieving pathway normalization rather than complete modulation.
- [Wyss-Coray T, et al., (2000) TGF-β1 reduces amyloid plaques in transgenic mice. Nature. PMID:10717490 (2000)
- [Tesseur I, et al., (2006) Deficiency in neuronal TGF-beta signaling accelerates Alzheimer's disease pathology. Nat Neurosci. PMID:17159942 (2006)
- [Unknown, Tesseur I, Wyss-Coray T (2006) A role for TGF-beta in Alzheimer's disease? Nat Med. PMID:16736028 (2006)
- [Sortwell CE, et al., (2000) TGF-β1 protects dopaminergic neurons. Exp Neurol. PMID:10817915 (2000)
- [Krieglstein K, et al., (1995) TGF-β protects dopaminergic neurons in vivo and in vitro. J Neurosci. PMID:7611521 (1995)
- [Chao CC, et al., (2009) TGF-β in Parkinson's disease neuroinflammation. Glia. PMID:19301341 (2009)
- [Endo R, et al., (2015) TGF-β signaling in ALS pathogenesis. Nat Commun. PMID:26522447 (2015)
- [Phatnani HP, et al., (2013) ALS with novel mutations. Nat Genet. PMID:23525077 (2013)
- [Blurton-Jones M, et al., (2009) Neural stem cells and TGF-β in Alzheimer's disease. Stem Cells. PMID:19543751 (2009)
- [Krieglstein K, et al., (2012) TGF-β in neurodegeneration. Exp Neurol. PMID:22155349 (2012)
- [Unknown, Ueberham U, Ueberham E (2020) TGF-β in Alzheimer's disease. J Neural Transm. PMID:32091847 (2020)
- [Wyss-Coray T, et al., (2001) TGF-β1 improves Aβ clearance. Nat Med. PMID:11231578 (2001)
- [Yousef H, et al., (2019) TGF-β and aging. Nature. PMID:31168087 (2019)
- [Van Hoecke A, et al., (2012) EPHA4 in ALS. Nat Med. PMID:22751994 (2012)
- Unknown, Galunisertib Trial NCT05328847. ClinicalTrials.gov (n.d.)